Compare Ascendis Pharma A/S (ASND) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs QUALCOMM, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while QUALCOMM, Inc. trades at $185.4 (market cap $199.37B). The key difference: QUALCOMM, Inc. is far larger — about 11.2× Ascendis Pharma A/S's market cap, and QUALCOMM, Inc. pays a 1.95% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | QCOM | |
|---|---|---|
Market Cap | $17.74B | $199.37B |
Sector | Health | Technology |
52-Week High | $277.18 | $251.10 |
52-Week Low | $163.32 | $124.07 |
Enterprise Value | $18.11B | $204.85B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Qualcomm (QCOM) trades at $189.16, down 1.01% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported revenue of $44.28 billion in 2025, with a net income margin of 22.31% and robust cash flow from operations of $14.01 billion. Recent news highlights its push into AI and data centers, though competition from Nvidia in the PC chip market poses challenges.
The outlook for QCOM is positive, driven by diversification into automotive and AI, with a consensus price target of $221.21 implying 17% upside. Risks include smartphone market softness and margin pressures, but strong analyst buy ratings (42.65%) and institutional support suggest confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
